{"DataElement":{"publicId":"5355415","version":"1","preferredName":"Bayer Classification of Visual Acuity Changes Grade","preferredDefinition":"Result of assessment for vision changes using a grading system for best corrected visual acuity following treatment with anetumab ravtansine (BAY 94-9343).","longName":"BAYER_VIS_ACUITY_GD","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"5354953","version":"1","preferredName":"Bayer Classification of Visual Acuity Changes Result","preferredDefinition":"A grading system for best corrected visual acuity following treatment with anetumab ravtansine (BAY 94-9343)._The result of an action.","longName":"5354951v1.0:2224045v1.0","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"5354951","version":"1","preferredName":"Bayer Classification of Visual Acuity Changes","preferredDefinition":"A grading system for best corrected visual acuity following treatment with anetumab ravtansine (BAY 94-9343).","longName":"C128445","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bayer Classification of Visual Acuity Changes","conceptCode":"C128445","definition":"A grading system for best corrected visual acuity following treatment with anetumab ravtansine (BAY 94-9343).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3829C2DF-47DA-6177-E050-BB89AD4341C5","latestVersionIndicator":"Yes","beginDate":"2016-07-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-21","modifiedBy":"ONEDATA","dateModified":"2016-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2224045","version":"1","preferredName":"Outcome","preferredDefinition":"A phenomenon that follows and is caused by some previous phenomenon.","longName":"C20200","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Outcome","conceptCode":"C20200","definition":"The result of an action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63F061C-D115-4EFF-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-03","endDate":null,"createdBy":"UMLLOADER_CAMOD","dateCreated":"2005-05-03","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3829C2DF-47E8-6177-E050-BB89AD4341C5","latestVersionIndicator":"Yes","beginDate":"2016-07-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-21","modifiedBy":"ONEDATA","dateModified":"2016-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5355121","version":"1","preferredName":"Bayer Classification of Visual Acuity Changes Grade","preferredDefinition":"A grading system for best corrected visual acuity following treatment with anetumab ravtansine (BAY 94-9343)._A position on a scale of intensity or amount or quality.","longName":"BAYER_VIS_ACUITY_GD","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"7","maxLength":"8","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Grade 4","valueDescription":"Bayer Visual Acuity Changes Grade 4","ValueMeaning":{"publicId":"5355164","version":"1","preferredName":"Bayer Visual Acuity Changes Grade 4","longName":"5355164","preferredDefinition":"Visual acuity loss greater than or equal to 6 lines, leading to blindness. (ETDRS equivalent: each loss of 3 lines corresponds to halving the visual acuity)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bayer Visual Acuity Changes Grade 4","conceptCode":"C128450","definition":"Visual acuity loss greater than or equal to 6 lines, leading to blindness. (ETDRS equivalent: each loss of 3 lines corresponds to halving the visual acuity)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"382A21AF-ABBD-1D57-E050-BB89AD435D89","latestVersionIndicator":"Yes","beginDate":"2016-07-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"382A21AF-ABD6-1D57-E050-BB89AD435D89","beginDate":"2016-07-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-21","modifiedBy":"ONEDATA","dateModified":"2016-07-21","deletedIndicator":"No"},{"value":"Grade 3","valueDescription":"Bayer Visual Acuity Changes Grade 3","ValueMeaning":{"publicId":"5355165","version":"1","preferredName":"Bayer Visual Acuity Changes Grade 3","longName":"5355165","preferredDefinition":"Visual acuity loss greater than or equal to 6 lines. (ETDRS equivalent: each loss of 3 lines corresponds to halving the visual acuity)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bayer Visual Acuity Changes Grade 3","conceptCode":"C128449","definition":"Visual acuity loss greater than or equal to 6 lines. (ETDRS equivalent: each loss of 3 lines corresponds to halving the visual acuity)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"382A21AF-ABE2-1D57-E050-BB89AD435D89","latestVersionIndicator":"Yes","beginDate":"2016-07-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"382A21AF-ABFB-1D57-E050-BB89AD435D89","beginDate":"2016-07-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-21","modifiedBy":"ONEDATA","dateModified":"2016-07-21","deletedIndicator":"No"},{"value":"Grade 2","valueDescription":"Bayer Visual Acuity Changes Grade 2","ValueMeaning":{"publicId":"5355166","version":"1","preferredName":"Bayer Visual Acuity Changes Grade 2","longName":"5355166","preferredDefinition":"Visual acuity loss greater than or equal to 3 lines, but less than 6 lines. (ETDRS equivalent: each loss of 3 lines corresponds to halving the visual acuity)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bayer Visual Acuity Changes Grade 2","conceptCode":"C128448","definition":"Visual acuity loss greater than or equal to 3 lines, but less than 6 lines. (ETDRS equivalent: each loss of 3 lines corresponds to halving the visual acuity)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"382A21AF-AC07-1D57-E050-BB89AD435D89","latestVersionIndicator":"Yes","beginDate":"2016-07-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"382A21AF-AC20-1D57-E050-BB89AD435D89","beginDate":"2016-07-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-21","modifiedBy":"ONEDATA","dateModified":"2016-07-21","deletedIndicator":"No"},{"value":"Grade 0","valueDescription":"Bayer Visual Acuity Changes Grade 0","ValueMeaning":{"publicId":"5355167","version":"1","preferredName":"Bayer Visual Acuity Changes Grade 0","longName":"5355167","preferredDefinition":"No findings, no reporting from the patient.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bayer Visual Acuity Changes Grade 0","conceptCode":"C128446","definition":"No findings, no reporting from the patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"382A21AF-AC2C-1D57-E050-BB89AD435D89","latestVersionIndicator":"Yes","beginDate":"2016-07-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"382A21AF-AC45-1D57-E050-BB89AD435D89","beginDate":"2016-07-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-21","modifiedBy":"ONEDATA","dateModified":"2016-07-21","deletedIndicator":"No"},{"value":"Grade 1","valueDescription":"Bayer Visual Acuity Changes Grade 1","ValueMeaning":{"publicId":"5355168","version":"1","preferredName":"Bayer Visual Acuity Changes Grade 1","longName":"5355168","preferredDefinition":"Symptomatic visual acuity loss of less than 3 lines. (ETDRS equivalent: each loss of 3 lines corresponds to halving the visual acuity)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bayer Visual Acuity Changes Grade 1","conceptCode":"C128447","definition":"Symptomatic visual acuity loss of less than 3 lines. (ETDRS equivalent: each loss of 3 lines corresponds to halving the visual acuity)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"382A21AF-AC51-1D57-E050-BB89AD435D89","latestVersionIndicator":"Yes","beginDate":"2016-07-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"382A21AF-AC6A-1D57-E050-BB89AD435D89","beginDate":"2016-07-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-21","modifiedBy":"ONEDATA","dateModified":"2016-07-21","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"5355120","version":"1","preferredName":"Bayer Classification of Visual Acuity Changes Grade","preferredDefinition":"A grading system for best corrected visual acuity following treatment with anetumab ravtansine (BAY 94-9343).:A position on a scale of intensity or amount or quality.","longName":"C128445:C48309","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bayer Classification of Visual Acuity Changes","conceptCode":"C128445","definition":"A grading system for best corrected visual acuity following treatment with anetumab ravtansine (BAY 94-9343).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Grade","conceptCode":"C48309","definition":"A position on a scale of intensity or amount or quality.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"382A21AF-A9B2-1D57-E050-BB89AD435D89","latestVersionIndicator":"Yes","beginDate":"2016-07-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-21","modifiedBy":"ONEDATA","dateModified":"2016-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"C3D:Central Cancer Clinical Database","workflowStatus":"RELEASED","registrationStatus":"Application","id":"382A21AF-A9C3-1D57-E050-BB89AD435D89","latestVersionIndicator":"Yes","beginDate":"2016-07-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-21","modifiedBy":"REEVESD","dateModified":"2016-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Visual Acuity","type":"Preferred Question Text","description":"Visual Acuity","url":null,"context":"CCR"}],"origin":"C3D:Central Cancer Clinical Database","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"38398293-0656-1D19-E050-BB89AD432BE0","latestVersionIndicator":"Yes","beginDate":"2016-07-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-22","modifiedBy":"REEVESD","dateModified":"2016-07-25","changeDescription":"Curated to support NCI CCR clinical trial.7.25.2016.dmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}